Classical and tissue RAAS, the ACE enzymatic hub, and the angiotensin II type 1 (AT1)/angiotensin II type 2 (AT2) receptor axes
ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are among the most widely prescribed drug classes in medicine. Their shared target, the renin-angiotensin-aldosterone system (RAAS), is the dominant neurohormonal driver of hypertension and cardiovascular remodeling, making these agents not merely antihypertensive drugs but disease-modifying therapies with outcome benefits that extend well beyond blood pressure reduction.1,2
The RAAS operates through two anatomically distinct but functionally integrated systems. The circulating RAAS proceeds from hepatic angiotensinogen cleavage by renin to produce angiotensin I, followed by pulmonary ACE-mediated conversion to angiotensin II (Ang II), which then drives systemic vasoconstriction, aldosterone release, and sodium retention. The tissue RAAS, expressed locally within the vasculature, heart, kidney, brain, and adrenal gland, generates Ang II that mediates vascular smooth muscle hypertrophy, myocardial fibrosis, and glomerular injury independent of circulating Ang II levels.1
The tissue compartment is now recognized as the principal mediator of long-term target organ damage. This is the key reason why RAAS inhibition confers organ protection beyond blood pressure reduction. ACE inhibitors and ARBs that penetrate tissue compartments effectively provide benefit that would not be predicted from hemodynamic effects alone.
Angiotensin-converting enzyme (ACE) is a zinc-containing dipeptidyl carboxypeptidase with two physiologically important substrates. First, ACE cleaves the C-terminal dipeptide from angiotensin I, generating the potent vasoconstrictor and pro-fibrotic peptide angiotensin II. Second, ACE is the principal enzyme responsible for degrading bradykinin, a vasodilatory, natriuretic, and antiproliferative peptide that stimulates nitric oxide and prostacyclin release from the endothelium.
This dual substrate activity explains two critical pharmacological consequences of ACE inhibition: reduced angiotensin II production (the primary antihypertensive and organ-protective mechanism) and bradykinin accumulation (which mediates additional vasodilation and underlies ACEi-specific adverse effects, particularly dry cough and angioedema).
AT1 receptors dominate cardiovascular pathophysiology, mediating vasoconstriction, aldosterone secretion, sodium and water retention, myocyte hypertrophy, fibroblast activation, interstitial fibrosis, sympathetic activation, vasopressin release, and reactive oxygen species generation in the endothelium. AT2 receptors, expressed at lower levels in adults, exert generally counterregulatory effects including nitric oxide (NO)-mediated vasodilation, antiproliferation, pro-apoptosis in vascular tissue, natriuresis, and cardioprotection.
A key pharmacological distinction between ACEi and ARBs: ACEi reduce Ang II production, lowering stimulation at both AT1 and AT2 receptors. ARBs block AT1 receptors selectively; the resulting loss of AT1-mediated feedback inhibition of renin leads to markedly elevated circulating Ang II, which drives increased AT2 receptor stimulation. Whether this differential AT2 receptor activation with ARBs confers clinically meaningful additional benefit remains a debated question.3
Mechanism, individual agents and pharmacokinetics, compelling indications, dosing principles, adverse effects, and contraindications
ACE inhibitors competitively inhibit the active site of ACE through coordination with its zinc ion. The net effects include reduced conversion of angiotensin I to Ang II (lower circulating and tissue Ang II), reduced AT1 receptor stimulation (decreased vasoconstriction, aldosterone secretion, sodium retention, and cardiac and renal remodeling), bradykinin accumulation (additional vasodilation via NO and prostacyclin; also mediates cough and angioedema), and reactive compensatory increase in plasma renin activity from loss of Ang II-mediated negative feedback on renin release.
The net hemodynamic effect is reduced total peripheral resistance as the primary blood pressure-lowering mechanism, mild natriuresis from reduced aldosterone-driven sodium retention, no significant reflex tachycardia (unlike direct vasodilators), and modest reduction in both preload and afterload that is clinically significant in heart failure.
| Agent | Prodrug | Elimination | Half-life | Landmark Trial / Clinical Niche |
|---|---|---|---|---|
| Captopril | No (active) | Renal | ~2 h | Acute settings (urgency, acute HF, acute MI); short action is an advantage; largely replaced for chronic HTN; sulfhydryl group causes rash and dysgeusia |
| Enalapril | Yes (enalaprilat) | Renal | ~11 h | CONSENSUS (1987): 40% mortality reduction in severe HFrEF (NYHA IV);5 IV enalaprilat available for emergencies |
| Lisinopril | No (active) | Renal (unchanged) | ~12 h | GISSI-3 (1994): 11% reduction in 6-week mortality post-MI;6 water-soluble; no hepatic activation; preferred with hepatic impairment |
| Ramipril | Yes (ramiprilat) | Renal + biliary | 13–17 h | HOPE (2000): 22% RRR in composite MI/stroke/CV death in high-risk patients without HF; 25% reduction in new diabetes;7 broadest indication profile |
| Perindopril | Yes (perindoprilat) | Renal | ~17 h | EUROPA (2003): 20% reduction in composite CV events in stable CAD without HF;8 widely used in Europe |
| Fosinopril | Yes | Dual: renal + hepatic | ~12 h | Preferred ACEi in advanced CKD; dual elimination minimizes accumulation |
| Trandolapril | Yes | Renal + biliary | ~24 h | TRACE trial: post-MI with LV dysfunction; long effective half-life permits once-daily dosing |
ACEi have compelling indications, defined as evidence-based outcome benefits independent of blood pressure lowering, in several specific clinical settings.1,2 In heart failure with reduced ejection fraction (HFrEF), ACEi are first-line guideline-directed medical therapy regardless of symptom severity, reducing mortality, hospitalizations, and disease progression, as established by the CONSENSUS and SOLVD trials.5 Post-myocardial infarction, particularly with left ventricular dysfunction, ACEi initiation reduces remodeling, progression to heart failure, and mortality.
In type 1 diabetic nephropathy, captopril reduced doubling of serum creatinine and end-stage renal disease (ESRD) by 50% in the Lewis et al. (1993) trial, independent of blood pressure effects.9 In chronic kidney disease with proteinuria, ACEi reduce proteinuria and slow progression regardless of etiology, as shown in the REIN trial with ramipril.10 In high cardiovascular risk without heart failure, the HOPE trial established that ramipril 10 mg/day reduces the composite of myocardial infarction, stroke, and cardiovascular death by 22%.7
As antihypertensives, ACEi are effective first-line agents, particularly in patients with the comorbidities above. They are less effective as monotherapy in Black patients due to lower-renin physiology but show comparable efficacy when combined with a diuretic or calcium channel blocker.1
Dry, non-productive cough is the most common ACEi-specific adverse effect, occurring in 5–20% of patients overall and up to 30–40% in patients of Asian descent due to pharmacogenomic variation in bradykinin metabolism. The mechanism is bradykinin accumulation in the respiratory tract stimulating sensory C-fibers, with prostaglandin E2 and substance P amplifying the response. Onset is typically within 1–4 weeks but can be delayed by months. Management requires switching to an ARB, as ARBs do not accumulate bradykinin and cough rates are comparable to placebo.
Angioedema affects approximately 0.1–0.5% of patients overall, with rates 3–4 times higher in Black patients. The mechanism is bradykinin-mediated increased vascular permeability in subcutaneous and submucosal tissues; this mechanism is not histamine-mediated. Laryngeal involvement is life-threatening. Management requires immediate discontinuation; airway management as needed; bradykinin B2 receptor antagonist (icatibant) or C1-esterase inhibitor concentrate for severe cases. Epinephrine and antihistamines have limited efficacy given the bradykinin rather than histamine mechanism. All ACEi must be permanently avoided after this event. ARBs may be cautiously used when a compelling indication exists, with the understanding that approximately 10% of patients with ACEi angioedema may experience ARB-associated angioedema.
Class adverse effects shared with ARBs include hyperkalemia from reduced aldosterone production; monitor potassium 1–2 weeks after initiation and with dose increases, and avoid triple RAAS blockade combining ACEi, ARB, and aldosterone antagonist.
Functional acute kidney injury may occur from efferent arteriolar dilation, particularly when renal perfusion is already compromised. A creatinine rise of up to 30% is expected and acceptable. Volume-depleted patients should have diuretic doses reduced before ACEi initiation when feasible. First-dose hypotension is more pronounced in volume-depleted or high-renin states; initiating at the lowest dose at bedtime reduces symptomatic risk.
Absolute contraindications to ACEi include pregnancy, prior ACEi-associated angioedema, bilateral renal artery stenosis or stenosis to a solitary functioning kidney, concurrent use with aliskiren in patients with diabetes or CKD with eGFR below 60 mL/min/1.73 m², and concurrent use with sacubitril/valsartan within 36 hours (risk of angioedema from bradykinin accumulation).
Mechanism, individual agents and key pharmacological distinctions, compelling indications, and adverse effects
ARBs are selective, competitive antagonists of the AT1 receptor. They do not affect ACE activity and therefore do not accumulate bradykinin.2,3 AT1 blockade prevents all Ang II-mediated AT1 effects: vasoconstriction, aldosterone release, sodium retention, sympathetic facilitation, and myocardial and glomerular remodeling. The loss of AT1-mediated renin suppression leads to a marked reactive rise in circulating Ang II, which then drives increased AT2 receptor stimulation, potentially providing vasodilatory, anti-fibrotic, and natriuretic effects. The absence of bradykinin accumulation explains why ARBs do not cause ACEi-type cough.
The hemodynamic profile of ARBs is essentially identical to ACEi: reduced total peripheral resistance, modest natriuresis, no reflex tachycardia, and comparable blood pressure-lowering efficacy.
| Agent | Elimination | Distinguishing Feature | Key Trial / Niche |
|---|---|---|---|
| Losartan | Hepatic (CYP2C9) + renal | Only ARB with uricosuric effect (URAT1 inhibition); mild serum urate reduction; advantageous in gout | LIFE (2002): 13% RRR vs atenolol in hypertensive patients with left ventricular hypertrophy (LVH); 25% stroke reduction;12 RENAAL (2001): type 2 diabetic nephropathy13 |
| Valsartan | Biliary/fecal (~83%); minimal renal | Primary ARB used in HF trials; valsartan component of sacubitril/valsartan (Entresto) | Val-HeFT (2001): HF hospitalizations;14 VALIANT (2003): non-inferior to captopril post-MI15 |
| Irbesartan | Hepatic + biliary | FDA-approved for type 2 diabetic nephropathy; strong renoprotective trial evidence | IDNT (2001): 20% RRR vs amlodipine in type 2 DN;16 IRMA-2 (2001): slowed progression from microalbuminuria17 |
| Candesartan | Renal + biliary | Highest AT1 receptor binding affinity; slowest dissociation ("insurmountable antagonism"); theoretical advantage during Ang II surges | CHARM trials (2003): HFrEF, heart failure with preserved ejection fraction (HFpEF), and ACEi-intolerant populations18 |
| Telmisartan | Almost exclusively biliary | Safest ARB in advanced CKD/ESRD; no dose adjustment required; partial PPAR-gamma agonist (metabolic benefit); longest half-life (~24 h) | ONTARGET (2008): non-inferior to ramipril in high CV risk; combination offers no benefit over monotherapy19 |
| Olmesartan | Renal + biliary | Highest lipophilicity; note: associated with sprue-like enteropathy (severe diarrhea and villous atrophy), which is rare but unique to this ARB | No major distinguishing outcome trial; effective antihypertensive |
| Azilsartan | Hepatic/biliary | Newest ARB; greatest 24-hour ambulatory BP reduction in head-to-head comparisons with olmesartan; limited long-term outcome data | Head-to-head BP reduction comparisons |
ARBs share most of the compelling indications of ACEi and are specifically indicated when ACEi are not tolerated, primarily due to cough or angioedema.1,2 In HFrEF in ACEi-intolerant patients, candesartan (CHARM-Alternative) and valsartan (Val-HeFT) are the evidence-based alternatives.14,18 In type 2 diabetes with nephropathy, irbesartan and losartan have the strongest direct trial evidence, and both are FDA-approved for renoprotection in this indication.13,16,17 Note that ACEi have stronger evidence in type 1 diabetic nephropathy. In hypertension with left ventricular hypertrophy, losartan was superior to atenolol in the LIFE trial for LVH regression and cardiovascular event reduction.12 ARBs also reduce incidence of new-onset type 2 diabetes compared with beta-blockers and diuretics, likely through improved insulin receptor signaling by reducing Ang II interference.
ARBs are the best-tolerated of all major antihypertensive drug classes. The absence of bradykinin accumulation means no ACEi-type cough (rate comparable to placebo) and no bradykinin-mediated angioedema. ARBs can generally be used after ACEi cough. Use with caution after ACEi angioedema, given rare cross-reactivity of approximately 10% has been reported, though ARBs are generally considered acceptable when a compelling indication outweighs the risk.
Class effects shared with ACEi (same mechanisms, same monitoring requirements) include hyperkalemia, functional acute kidney injury, first-dose hypotension, and teratogenicity. Olmesartan-associated sprue-like enteropathy is a rare but specific adverse effect of that agent, causing severe malabsorption with villous atrophy resolves on discontinuation and should be distinguished from celiac disease before reaching a diagnosis.
When to choose which class, and why to avoid dual RAAS blockade
For most clinical purposes, ACEi and ARBs produce equivalent outcomes, including comparable blood pressure reduction in magnitude and speed of onset, comparable mortality benefit in HFrEF, comparable renal protection in diabetic nephropathy, and comparable reduction in cardiovascular events in high-risk patients (ONTARGET).19 The ONTARGET trial established that telmisartan was non-inferior, but not superior, to ramipril in high cardiovascular risk patients.
Combining an ACEi with an ARB was hypothesized to provide additive benefit. The evidence does not support this strategy for most patients.19,20 The ONTARGET trial (2008) compared ramipril plus telmisartan versus either agent alone in high cardiovascular risk patients.19 The combination offered no reduction in the primary cardiovascular endpoint compared with either agent alone, but produced significantly more hypotension, syncope, acute kidney injury (approximately twice the rate), and hyperkalemia. The VA NEPHRON-D trial (2013) examined dual blockade with losartan plus lisinopril in type 2 diabetic nephropathy and was terminated early due to excess acute kidney injury and hyperkalemia with no renal outcome benefit.20
Aliskiren is the only approved direct renin inhibitor, blocking the first and rate-limiting step of the RAAS cascade. Its clinical role is limited. The ALTITUDE trial (2012) of aliskiren added to an ACEi or ARB in patients with type 2 diabetes with CKD and/or cardiovascular disease was terminated early due to increased stroke, renal complications, hyperkalemia, and hypotension.21 Aliskiren is contraindicated in combination with ACEi or ARBs in patients with diabetes (absolute) or CKD with eGFR below 60 mL/min/1.73 m² (absolute). Its role as monotherapy is modest, and it has largely been supplanted by ARBs as the alternative for ACEi-intolerant patients.
Laboratory surveillance after initiation or dose increase, and sick-day guidance
Following initiation or dose increase of an ACEi or ARB, serum creatinine and eGFR should be checked 1–2 weeks afterward and after each subsequent dose increase.1,2 A rise of up to 30% from baseline is acceptable and expected, as this is the mechanism of renoprotection, not nephrotoxicity. A rise of more than 30% warrants dose reduction and identification of precipitating factors (volume depletion, concurrent NSAIDs, iodinated contrast exposure). A rise of more than 50% or acute severe acute kidney injury warrants holding the drug and reassessing the indication.
Serum potassium should also be checked 1–2 weeks after initiation. A potassium of 5.0–5.5 mEq/L warrants dose reduction, dietary potassium counseling, and review of interacting medications. Potassium above 5.5 mEq/L warrants holding the drug. Blood pressure should be assessed 2–4 weeks after initiation, sooner in high-risk patients, with evaluation for symptomatic first-dose hypotension. For stable patients with chronic kidney disease on long-term RAAS inhibition, renal function and potassium should be checked every 3–6 months. Patients without chronic kidney disease should have annual checks.
Sick-day guidance is an important but often overlooked component of RAAS inhibitor management. Patients should be advised to temporarily hold their ACEi or ARB (and any diuretics) during acute illnesses associated with volume depletion, including vomiting, diarrhea, or fever with poor oral intake, to prevent acute kidney injury. This guidance should be provided at initiation and reinforced at follow-up visits.